Updates on CAR-T in Multiple Myeloma

 

Indy Hematology Review
Avatar

Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Current Therapy

By Indy Hematology Review FEATURING Kenneth Anderson
By Indy Hematology Review FEATURING Kenneth Anderson
1,302 views
January 18, 2023
0 Comments
Login to view comments. Click here to Login
Updates on CAR-T in Multiple Myeloma
06:12
Maximilian Merz

Patient Selection for Ciltacabtagene Autoleucel Therapy in R/R MM

11:43
UCSF School of Medicine

CARTITUDE-1: 2 Years Post-LPI Update on the Phase 1b/2 Study of Cilt…

Feat. T. Martin
15:29
SOHO Brazil 2022

SOHO Brazil 2022 on CAR-T in Refractory MM: When Is the Precise Mome…

Feat. M. Bishop, P. Scheinberg
21:16
UChicago Medicine

Myeloma 2022: Challenges and Path Forward

Feat. A. Jakubowiak
04:08
GRACE

CAR T-Cell Therapy Side Effects for Blood Cancers

Feat. A. Goodman
21:38
Rahul Banerjee

CAR-T Therapy in Myeloma: What's Here and What's Coming So…

12:11
SOHO 2022 Tenth Annual Meeting

SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Pro C…

Feat. T. Martin
14:22
SOHO 2022 Tenth Annual Meeting

SOHO 2022: CAR T-Cell in MM - When To Use Now, Where Are We Going?

Feat. N. S. Raje
19:05
UChicago Medicine

Identifying and Managing Major Toxicities of CAR-T Therapy in Multip…

Feat. S. Kosuri
05:32
Enrique Ocio

Triple Refractory MM Patients: Learnings From the MAMMOTH and the Lo…

08:13
Shaji Kumar

CAR-T in MM: Benefits of a Treatment-Free Interval

06:58
Saurabh Chhabra

Summary of the MAMMOTH Trial in R/R Myeloma

14:41
Zhubin Gahvari

MAMMOTH Trial: Myeloma Outcomes Post Anti-CD38 MoAbs

05:05
ASH 2022 Conference Coverage

ASH 2022 Outcomes of Penta-Refractory MM Patients Based on Access to…

Feat. S. Atrash
14:03
ASH 2022 Conference Coverage

ASH 2022 Neurotoxicity With Motor Symptoms After BCMA-Directed CAR-T…

Feat. S. Parekh
31:51
Indy Hematology Review

Treating Multiple Myeloma: The Cure Is Within Reach - Goals of Curre…

Feat. K. Anderson